Positive early data de-risks the HCW9302 program and supports the Treg-selective mechanism. Monitor for third cohort data and RP2D announcement by year-end 2026. The small sample size (n=3 at 3 mcg/kg) limits statistical significance, so further dose escalation results will be critical for valuation.
Price Chart
Executive Summary
HCW Biologics reported positive preliminary Phase 1 data for HCW9302 in alopecia areata: all three patients in the second dose cohort (3 mcg/kg) achieved ≥25% SALT score reduction with no dose-limiting toxicities or IL-2-related adverse events. The differentiated safety profile and Treg-selective mechanism support advancement toward RP2D by year-end 2026, but the tiny sample (n=3) and early stage limit conviction.
Key Facts
- All three patients in the 3 mcg/kg cohort showed ≥25% SALT score reduction at 4 and/or 9 weeks post single dose.
- No capillary leak, cytokine release syndrome, or eosinophil increase reported; adverse events were mild injection-site reactions.
- Company projects to establish Recommended Phase 2 Dose by year-end 2026; third dose cohort (8 mcg/kg) dosing underway.
- HCW9302 is a first-in-kind IL-2-based fusion immunotherapeutic with strong IL-2Rα bias, differentiating it from native IL-2 and other IL-2 variants.
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech with $9M market cap.
Risk Factors
- Extremely small sample size (n=3 in second cohort); results may not replicate in larger populations.
- Phase 1 only; safety and efficacy in later-stage trials remain unproven.
- Company has $9M market cap and is pre-revenue; financing risk if clinical development requires additional capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312406 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | EFFECT | $1.26 | awaiting T+60 | — | $1.12 (+11.11%) |
Oct 2, 2026 24d ago | S-1 | $1.64 | awaiting T+60 | — | $1.12 (+31.71%) |
Oct 1, 2026 26d ago | DEF 14A | $1.69 | awaiting T+60 | — | $1.12 (+33.73%) |
Sep 24, 2026 4w ago | 8-K | $1.99 | awaiting T+60 | — | $1.12 (+43.72%) |
Aug 20, 2026 9w ago | S-1 | $2.12 | awaiting T+60 | — | $1.12 (−47.17%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.12 (+58.21%) |
Aug 14, 2026 10w ago | Press Release | $2.68 | awaiting T+60 | — | $1.12 (+58.21%) |
Aug 14, 2026 10w ago | 10-Q/A | $2.68 | awaiting T+60 | — | $1.12 (+58.21%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.12 (+58.21%) |
Jul 29, 2026 12w ago | Press Release | $2.58 $1.12 | ▲ +56.59% | ▲ +61.32% | $1.12 (+56.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers